Apple Tree Venture Management Llc
Venture capitalNew York · Pre-Seed–Late Stage · 18 people tracked
Investment thesis
Apple Tree Partners focuses on developing next-generation biotechnology companies by creating science-based enterprises from inception through maturity. The firm invests across multiple stages, from collaborating with scientists on pre-commercialization ideas to supporting spinouts from existing pipelines. It provides comprehensive support including flexible capital, strategic insights, and operational resources to build sustainable, research-driven companies.
Source: firm website, verified Jul 21, 2026.
Team · 18 people
from the firm's websiteManaging director of Apple Tree Partners GP III Ltd., leading the firm through ongoing Chapter 11 restructuring proceedings.
Founder and managing partner of Apple Tree Partners, with a career in life sciences investing dating back to 1991. He previously served as a general partner at Oak Investment Partners and venture partner at Sevin Rosen Funds, with early investments in multiple companies that went public or were acquired.
Partner based in London who joined ATP in 2016 from Braeburn, an ATP portfolio company where she held senior strategic roles. She previously served as senior vice president and head of Capital Markets and Investor Relations at Uralkali, leading a prominent London Stock Exchange IPO.
Principal of new product planning who previously held senior director roles at Sanofi Genzyme in rare disease commercialization and established the business insights function at Foundation Medicine. She began her career as a healthcare equity research analyst at multiple investment banks.
Senior principal and science-driven investor with over 15 years of biotech venture capital experience. She previously served as director at Quark Venture and QB3, leading due diligence and board roles for multiple biotech investments, with a PhD in chemistry from Caltech.
Venture partner with over 20 years of experience founding and funding life science companies. He co-founded ATP portfolio companies Aileron Therapeutics and Tokai Pharmaceuticals, leading the latter's growth and Aileron's $1.1 billion partnership with Roche and IPO.
Venture partner with three decades of drug product development experience who founded and successfully exited three companies: sunSmart, Particle Sciences, and Mind Sciences. He has numerous peer-reviewed publications and over 25 patents across drug delivery, diagnostics, and medical devices.
Venture partner with 25 years of pharmaceutical research and development experience at Pfizer, where he led cardiovascular and metabolic disease research and discovered over 50 clinical candidates. He founded Staten Biotechnology, which was acquired by Novo Nordisk, and has contributed to ATP portfolio company outcomes.
Chief medical officer and venture partner with over 30 years of drug development experience at Eli Lilly and Amgen, where he led cardiovascular discovery, translational medicine, regulatory affairs, and global medical programs. He holds over 80 peer-reviewed publications and was a professor of medicine and director of cardiac intensive care.
Venture partner with decades of pharmaceutical research leadership at Biogen and Pfizer, where he led medicinal chemistry teams and established external portfolio innovation programs. He holds a PhD in organic chemistry and serves as an adjunct professor at UCSF's pharmaceutical chemistry department.
Entrepreneur in residence focused on innovative protein engineering with over 20 years of hands-on experience designing novel proteins. He held leadership roles at Elstar Therapeutics and Novartis, developing bispecific antibody platforms and contributing to CAR-T therapy patents.
General counsel with over 45 years of experience as a corporate and partnership attorney specializing in private investment funds. He has served as ATP's principal funds counsel for 20 years and previously represented funds raising over $50 billion in committed capital.
Head of talent with over a decade of executive search experience, including six years recruiting C-level leaders into VC-backed companies. She previously led Biogen's in-house executive search capability and led their leadership succession planning and executive onboarding programs.
Entrepreneur in residence with over 20 years of biopharmaceutical leadership and drug discovery experience. He previously served as senior vice president of biology at Goldfinch Bio and held leadership roles at Catabasis Pharmaceuticals, Novartis, and Merck Research Laboratories.
Head of operations with over 30 years of experience supporting private investment funds. She has worked with ATP since its inception in 1999 and previously worked at H/2 Capital Partners for nearly a decade, managing operations, administration, human resources, legal and compliance matters.
Head of communications with over 25 years of biopharmaceutical industry experience. She held leadership roles in corporate affairs and communications at Pfizer, Amgen, and Bristol-Myers Squibb, focusing on research transparency, clinical trials awareness, and public health education.
Scientist in residence focused on innovative protein engineering who previously contributed to protein technology platforms at Akrevia Therapeutics and Elstar Therapeutics. She is a co-inventor on multiple patents for bi-specific antibodies and protein therapeutics.
Special advisor and partner at Wilson Sonsini Goodrich and Rosati with three decades of experience formulating IP and legal strategies for life science companies. He was previously general counsel at Perlegen Sciences and Affymetrix, and lectures in biotechnology law at UC Berkeley.
What they invest in
from 18 of 59 portfolio companiesBiotech ×13Healthtech ×9Medical Devices ×8AI & Machine Learning ×6Deep Tech ×5Digital Health ×2Defense Tech ×1GovTech ×1
HQs:United States×12Denmark×1United Kingdom×1Mexico×1
Investments · 59 tracked
founders shown can be your intro pathMedtronic designs and develops medical technology for treating complex diseases. The company redesigns treatment for more than 70 serious health conditions through applied healthcare technology, artificial intelligence, and medical devices.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Smith+Nephew is a medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue, serving orthopedic and sports medicine patients.
HealthtechMedical DevicesLondon, GB
Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally. The organization develops pharmaceuticals, medical devices, and healthcare solutions across therapeutic areas including cardiology, oncology, immunology, neuroscience, and orthopaedics, alongside digital health and surgical robotics technologies.
BiotechHealthtechMedical DevicesNew Brunswick, US
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.
BiotechHealthtechMedical Devices
ATP develops life sciences companies, operating in the biotech/deeptech sector.
BiotechDeep Tech
Aulos develops immune-activating antibody therapeutics for cancer treatment, using artificial intelligence to design monoclonal antibodies that modulate interleukin-2 activity to enhance immune activation in immuno-oncology.
AI & Machine LearningBiotechHealthtech
Braeburn Rx is transforming the management and treatment of opioid use disorder (OUD) by working to eliminate stigma and improve access to care. The company operates in the digital health and addiction treatment space, focusing on recovery solutions for people affected by opioid use disorder.
Digital HealthHealthtechPhiladelphia, US
Novo Nordisk is a pharmaceutical company that develops and markets treatments for diabetes, hemophilia, weight management, and other chronic diseases through innovative drug therapies.
BiotechHealthtechMedical DevicesCopenhagen, DK
Smiths Detection manufactures X-ray screening systems, explosive and narcotics detection equipment, and security checkpoint solutions for airports, borders, and cargo facilities. The company serves aviation, transportation, and government security agencies with advanced detection and inspection technologies.
Defense TechGovTechHardware
Deep Apple Therapeutics is discovering small-molecule drug candidates using cryo-EM structural biology, artificial intelligence, and virtual screening to identify compounds for various diseases. The company serves pharmaceutical development and biomedical research.
AI & Machine LearningBiotechDeep Tech
Evercrisp develops machine learning-engineered miniproteins that enable targeted delivery of genetic medicine payloads to previously inaccessible tissues without relying on viral vectors or nanoparticles. The company serves patients with limited treatment options across diverse genetic diseases by making genome editing and oligonucleotide therapies safer and more effective.
AI & Machine LearningBiotechDeep Tech
Jennifer Doudna, Ph.D.Tanja Kortemme, Ph.D.Spiros Liras, Ph.D.
Galvanize Therapeutics develops Aliya, a pulsed electric field (PEF) energy platform for surgical ablation of soft tissue that uses regulated cell death mechanisms. The company serves surgeons and interventional pulmonologists treating cancer and other soft tissue conditions.
BiotechMedical Devices
Marengo Therapeutics develops TCR-targeting antibodies to activate T cell subsets against cancer. The clinical-stage biotech company uses novel immunotherapy approaches to enable the body's immune system to mount durable responses to cancer and other diseases.
BiotechHealthtech
Nine Square Therapeutics develops drugs targeting neurodegenerative diseases, focusing on identifying and validating novel drug targets previously considered undruggable. The company combines experimental biology, computational methods, and systems-level approaches to advance treatments for conditions including Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal lobar degeneration.
AI & Machine LearningBiotechDeep TechSan Francisco, US
LaniSteveMatthew P. JacobsonSpiros
Replicate Bioscience develops self-replicating RNA (srRNA) vector platform technology for therapeutic treatments across infectious disease, oncology, and autoimmune disorders. The company's approach leverages srRNA to drive repeated production of natural RNA within cells, enabling sustained protein expression and therapeutic effects.
AI & Machine LearningBiotechDeep TechSan Diego, US
Alexion is a biopharmaceutical company focused on researching and developing treatments for rare diseases, investigating new targets, modalities and technologies to address patient needs globally.
BiotechBoston, US
Abbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
HealthtechMedical Devices
Eledon develops tegoprubart, an anti-CD40L antibody immunosuppressant for organ transplant recipients, aimed at preventing transplant rejection and extending organ longevity. The company is conducting clinical trials in kidney transplantation with expansion into liver transplants and xenotransplantation.
BiotechLongevityMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Board seats · per SEC filings · 7
what is this? ⓘ$20M raise · filed Aug 2023 · via Anna Batarina, Seth Harrison
$53M raise · filed Mar 2022 · via Joseph Yanchik, Seth Harrison
$65M raise · filed Feb 2022 · via Joseph Yanchik, Seth Harrison
$52M raise · filed Dec 2021 · via Paul Da Silva Jardine, Seth Harrison
$55M raise · filed Nov 2021 · via Seth Harrison, Spiros Liras
$75M raise · filed Aug 2021 · via Anna Batarina, Seth Harrison
$50M raise · filed Nov 2020 · via Paul Eisenberg, Seth Harrison
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Apple Tree Venture Management Llc invest at?
- Apple Tree Venture Management Llc invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Apple Tree Venture Management Llc focus on?
- Apple Tree Venture Management Llc focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Apple Tree Venture Management Llc located?
- Apple Tree Venture Management Llc is headquartered in New York, US.
Images
Similar investors
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.